A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.

Phase 2

Recruiting

• Conditions: breast cancer

• Registration Number: JPRN-UMIN000017382
• Lead Sponsor: Tokyo Women's Medical University,Department of endocrine surgery

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-05-01
• Study Completion: 2018-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

History of drug-hypersensitivity. No previous treatments for breast cancer (within 5 years) . Active double cancer. Synchronous bilateral breast cancer excluding contralateral non-invasive cancer (DCIS/LCIS). Male patient. Infection or suspected infection. Serious cardiac disorder or preexisting cardiac disease. Uncontrolled diabetes. Gastrointestinal ulceration or gastrointestinal bleeding Current pregnancy and lactation, or possibility of pregnancy. Ineligible based on decision of an investigator. preexisting cardiac disease. Uncontrolled diabetes. Gastrointestinal ulceration or gastrointestinal bleeding. Current pregnancy and lactation, or possibility of pregnancy. Ineligible based on decision of an investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pathological Complete Response Rate

Secondary Outcome Measures

Name	Time	Method
Overall response rate Safety Breast conservation rate Disease-free survival